FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Pegram

Research Profile

Disorders

Chemicals & Drugs

Procedures

Antineoplastic Combined Chemotherapy Protocols

Genes & Molecular Sequences

Genes, erbB-2

Living Beings

Concepts & Ideas

Physiology

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Toby M Ward; C Rodriguez; S Singh; S Dean; M Gallas; N Hoe; Elizabeth Jane Iorns; A-M Jegg; P Kim; Ralf Landgraf; Marc Lippman; X Liu; Mark D Pegram
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Judith Hurley; Rene Larrieu; Jose Pablo Leone; Isildinha M Reis; Steven E Rodgers; Jean Wright; Carmen Gomez; Mark D Pegram
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Anna-Maria Jegg; Ralf Landgraf; Xiaofei Liu; Nicholas Hoe; Elizabeth Jane Iorns; Sharat Singh; Toby M Ward; Jinyao Zhou; Mark D Pegram
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Pegram (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Toby M Ward; C Rodriguez; S Singh; S Dean; M Gallas; N Hoe; Elizabeth Jane Iorns; A-M Jegg; P Kim; Ralf Landgraf; Marc Lippman; X Liu; Mark D Pegram
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Oncogene 2013;32(19):2463-74.
2013: Judith Hurley; Rene Larrieu; Jose Pablo Leone; Isildinha M Reis; Steven E Rodgers; Jean Wright; Carmen Gomez; Mark D Pegram
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Breast cancer research and treatment 2013;138(3):783-94.
2012: Anna-Maria Jegg; Ralf Landgraf; Xiaofei Liu; Nicholas Hoe; Elizabeth Jane Iorns; Sharat Singh; Toby M Ward; Jinyao Zhou; Mark D Pegram
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Breast cancer research and treatment 2012;136(3):683-92.
2012: Elizabeth Jane Iorns; Clare M Isacke; Anna Jegg; Iwanka Kozarewa; Alan Ashworth; Sonja Dean; Kerry Fenwick; Harry Hnatyszyn; Christopher J Lord; Costas Mitsopoulos; Nirupa Murugaesu; Cristina Naceur-Lombarelli; Mark D Pegram; David Sims; Dafydd Thomas; Toby M Ward; Marketa Zvelebil; Marc Lippman
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.
Breast cancer research and treatment 2012;135(1):79-91.
2012: Mark D Pegram; J Liao
Trastuzumab treatment in multiple lines: current data and future directions.
Clinical breast cancer 2012;12(1):10-8.
2012: Alberto Montero; Mark D Pegram; T Rumboldt; K Schuhwerk; Pearl Seo; Orlando Silva; Joyce M Slingerland; Catherine Welsh; S Yasir; Eli Avisar; Y E Deutsch; Claudia Diaz; E Garret-Mayer; Judith Hurley DeLeo; Merce Jorda; Leonidas G Koniaris; Stefan Gluck
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.
Breast cancer research and treatment 2012;132(1):215-23.
2011: Nuhad K Ibrahim; Volodymyr Komisarenko; Yaroslav Shparyk; Vladimir Semiglazov; Kemal O Yariz; Alexei Manikhas; Fredrik Erlandsson; David Jones; Shai Senderovich; Gary Acton; Anna Alyasova; Albert Chau; James Lee Murray; Ihor Bondarenko; Mark D Pegram
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6822-30.
2011: Nehmat Houssami; Petra Macaskill; Rosemary L Balleine; Michael Bilous; Mark D Pegram
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
Breast cancer research and treatment 2011;129(3):659-74.
2011: Tasha R Smith; Beth O Van Emburgh; Glenn O Allen; Jeff W Hill; Laura Kresty; Edward A Levine; Wen Liu; Mark S Miller; Mark D Pegram; Isildinha M Reis; Jennifer Hu
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.
Carcinogenesis 2011;32(9):1354-60.
2011: Kazuhiro Araki; Mark D Pegram
Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
Breast cancer research and treatment 2011;127(2):589-90.
2011: Sumanta Kumar Pal; Barrett H Childs; Mark D Pegram
Triple negative breast cancer: unmet medical needs.
Breast cancer research and treatment 2011;125(3):627-36.
2011: Vicente Valero; John Forbes; Mark D Pegram; Tadeusz Pienkowski; Wolfgang Eiermann; Gunter von Minckwitz; Henri Roche; Miguel Martin; John Crown; John R Mackey; Pierre Fumoleau; Janusz Rolski; Zrinka Mrsic-Krmpotic; Agnieszka Jagiello-Gruszfeld; Alessandro Riva; Marc Buyse; Henry Taupin; Guido Sauter; Michael F Press; Dennis J Slamon
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(2):149-56.
2010: Kathy S Albain; Lisa Carey; William J Gradishar; Julie R Gralow; Allan Lipton; Hope Rugo; Debu Tripathy; Susan Peck; Tristin Abair; Mark D Pegram
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
Clinical breast cancer 2010;10(6):421-39.
2010: B Royer; W Yin; Mark D Pegram; N Ibrahim; C Villanueva; D Mir; F Erlandsson; X Pivot
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.
British journal of cancer 2010;102(5):827-32.
2010: Sumanta K Pal; Barrett H Childs; Mark D Pegram
Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
Breast cancer research and treatment 2010;119(1):25-32.
2009: Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark D Pegram
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5538-46.
2009: K L Blackwell; Mark D Pegram; E Tan-Chiu; L S Schwartzberg; M C Arbushites; J D Maltzman; J K Forster; S D Rubin; S H Stein; H J Burstein
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(6):1026-31.
2009: Mark D Pegram; Virginia F Borges; Nuhad Ibrahim; Jyotsna Fuloria; Charles Shapiro; Susan Perez; Karen Wang; Franziska Schaedli Stark; Nigel Courtenay Luck
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Breast cancer research : BCR 2009;11(5):R73.
2008: Anna Maria Storniolo; Mark D Pegram; Beth Overmoyer; Paula Silverman; Nancy W Peacock; Suzanne F Jones; Jill Loftiss; Nikita Arya; Kevin M Koch; Elaine Paul; Lini Pandite; Ronald A Fleming; Peter F Lebowitz; Peter T C Ho; Howard A Burris
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3317-23.
2008: Mark D Pegram; Edith A Perez; Martine Piccart; Neil Spector
Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
Clinical breast cancer 2008;8 Suppl 3():S131-41.
2008: Mark D Pegram
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
Clinical breast cancer 2008;8 Suppl 3():S121-30.
2007: Amanda L Kesner; Wei-Ann Hsueh; Nwe Linn Htet; Betty Pio; Johannes Czernin; Mark D Pegram; Michael E Phelps; Daniel H S Silverman
Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(12):2021-7.
2007: Sumanta Kumar Pal; Mark D Pegram
HER2 targeted therapy in breast cancer...beyond Herceptin.
Reviews in endocrine & metabolic disorders 2007;8(3):269-77.
2007: Clare Taylor; Dawn Hershman; Nina Shah; Nicole Suciu-Foca; Daniel P Petrylak; Robert N Taub; Linda Vahdat; Bin Cheng; Mark D Pegram; Keith L Knutson; Raphael Clynes
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5133-43.
2007: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Archives of pathology & laboratory medicine 2007;131(1):18-43.
2007: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy S Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):118-45.
2006: Wei-Ann Hsueh; Amanda L Kesner; Anne Gangloff; Mark D Pegram; Malgorzata Beryt; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(12):1995-9.
2006: Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4324-32.
2006: Mark D Pegram; Debbie Ngo
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.
Advanced drug delivery reviews 2006;58(5-6):723-34.
2006: Sumanta Kumar Pal; Mark D Pegram
Targeting HER2 Epitopes.
Seminars in oncology 2006;33(4):386-91.
2006: Lori Jerome; Nezha Alami; Sylvie Belanger; Viviane Page; Qingnan Yu; Jesse Paterson; Laura Shiry; Mark D Pegram; Brian Leyland-Jones
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Cancer research 2006;66(14):7245-52.
2006: Jocelyn Holash; Gavin Thurston; John S Rudge; George D Yancopoulos; Alex A. Adjei; Gabriele Bergers; Bronislaw Pytowski; Mark D Pegram; Michael S Gordon
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
Cancer metastasis reviews 2006;25(2):243-52.
2006: Judith Hurley DeLeo; Philomena Doliny; Isildinha M Reis; Orlando Silva; Carmen Gomez; Pedro Velez; Giovanni Pauletti; Jodeen E Powell; Mark D Pegram; Dennis J Slamon
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1831-8.
2006: B M Ryan; Gottfried E Konecny; S Kahlert; H-J Wang; M Untch; G Meng; Mark D Pegram; K C Podratz; John Crown; Dennis J Slamon; Michael J Duffy
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):597-604.
2006: Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Cancer research 2006;66(3):1630-9.
2006: Betty Pio; Cecilia K Park; Richard J Pietras; Wei-Ann Hsueh; Nagichettiar Satyamurthy; Mark D Pegram; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2006;8(1):36-42.
2005: Kathy S Albain; Jaime De la Garza-Salazar; Tadeusz Pienkowski; Matti Aapro; Jonas Bergh; Maira Caleffi; Robert Coleman; Wolfgang Eiermann; Fikri Icli; Mark D Pegram; Martine Piccart; Raymond Snyder; Masakazu Toi; Gabriel N Hortobagyi
Reducing the global breast cancer burden: the importance of patterns of care research.
Clinical breast cancer 2005;6(5):412-20.
2005: Anne Gangloff; Wei-Ann Hsueh; Amanda L Kesner; Dale O Kiesewetter; Betty Pio; Mark D Pegram; Malgorzata Beryt; Allison Townsend; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(11):1866-71.
2005: Melvin J Silverstein; Michael D Lagios; Abram Recht; D Craig Allred; Steven Harms; Roland Holland; Dennis R Holmes; Lorie L Hughes; Roger J Jackman; Thomas B Julian; Henry M Kuerer; Helen Mabry; David R McCready; Kelly M McMasters; David L Page; Steve H Parker; Helen A Pass; Mark D Pegram; Eva Rubin; A Thomas Stavros; Debu Tripathy; Frank Vicini; Pat W Whitworth
Image-detected breast cancer: state of the art diagnosis and treatment.
Journal of the American College of Surgeons 2005;201(4):586-97.
2005: Christina H Yeon; Mark D Pegram
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
Investigational new drugs 2005;23(5):391-409.
2005: Sumanta Kumar Pal; Mark D Pegram
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy.
Anti-cancer drugs 2005;16(5):483-94.
2005: Mark D Pegram; Richard J Pietras; Alex Bajamonde; Pamela Klein; Gwen Fyfe
Targeted therapy: wave of the future.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(8):1776-81.
2004: Gottfried E Konecny; Mark D Pegram
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Oncology (Williston Park, N.Y.) 2004;18(14 Suppl 12):32-6.
2004: Christos Emmanouilides; Mark D Pegram; R Robinson; R Hecht; Fairooz Kabbinavar; William H Isacoff
Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.
Techniques in coloproctology 2004;8 Suppl 1():s50-2.
2004: Mark D Pegram
Breast cancer: review of platinum-based cooperative group trials.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 2():S2-9.
2004: Gottfried E Konecny; Christoph Thomssen; Hans-Joachim Lück; Michael Untch; He-Jing Wang; Walther Kuhn; Holger Eidtmann; Andreas du Bois; Sigrid Olbricht; Dieter Steinfeld; Volker Möbus; Gunter von Minckwitz; Sugandha Dandekar; Lillian Ramos; Giovanni Pauletti; Mark D Pegram; Fritz Jänicke; Dennis J Slamon
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Journal of the National Cancer Institute 2004;96(15):1141-51.
2004: Mark D Pegram; Tadeusz Pienkowski; Donald W Northfelt; Wolfgang Eiermann; Ravi Patel; Pierre Fumoleau; Eleonor Quan; John Crown; Deborah Toppmeyer; Michael Smylie; Alessandro Riva; Sandra Blitz; Michael F Press; David M Reese; Mary-Ann Lindsay; Dennis J Slamon
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Journal of the National Cancer Institute 2004;96(10):759-69.
2004: Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard J Pietras; Dennis J Slamon
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Journal of the National Cancer Institute 2004;96(10):739-49.
2004: Gottfried E Konecny; Y Gloria Meng; Michael Untch; He-Jing Wang; Ingo Bauerfeind; Melinda Epstein; Petra Stieber; Jean-Michel Vernes; Johnny Gutierrez; Kyu Hong; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1706-16.
2003: Gottfried E Konecny; Giovanni Pauletti; Mark D Pegram; Michael Untch; Sugandha Dandekar; Zuleima Aguilar; Cindy Wilson; Hong-Mei Rong; Ingo Bauerfeind; Margret Felber; He-Jing Wang; Malgorzata Beryt; Ram Seshadri; Hermann Hepp; Dennis J Slamon
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Journal of the National Cancer Institute 2003;95(2):142-53.
2003: John Crown; Mark D Pegram
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Breast cancer research and treatment 2003;79 Suppl 1():S11-8.
2003: Carl Gilbert; Eleanor B McGowan; Gerald B Seery; Kirby S Black; Mark D Pegram
Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Journal of experimental therapeutics & oncology 2003;3(1):27-35.
2002: John C Elkas; Rae Lynn Baldwin; Mark D Pegram; Yiou Tseng; Dennis J Slamon; Beth Y Karlan
A human ovarian carcinoma murine xenograft model useful for preclinical trials.
Gynecologic oncology 2002;87(2):200-6.
2002: Richard E Buller; Mark S Shahin; Jo Ann Horowitz; Ingo B Runnebaum; Vikas Mahavni; Stan Petrauskas; Rolf Kreienberg; Beth Y Karlan; Dennis J Slamon; Mark D Pegram
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Cancer gene therapy 2002;9(7):567-72.
2002: Richard E Buller; Ingo B Runnebaum; Beth Y Karlan; Jo Ann Horowitz; Mark S Shahin; Thomas E Buekers; Stan Petrauskas; Rolf Kreienberg; Dennis J Slamon; Mark D Pegram
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Cancer gene therapy 2002;9(7):553-66.
2002: Mark D Pegram; David M Reese
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Seminars in oncology 2002;29(3 Suppl 11):29-37.
2002: Saskia T C Neuteboom; Patricia L Karjian; Christopher R Boyer; Malgorzata Beryt; Mark D Pegram; Geoffrey M Wahl; H Michael Shepard
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
Molecular cancer therapeutics 2002;1(6):377-84.
2002: Christopher R Boyer; Patricia L Karjian; Geoffrey M Wahl; Mark D Pegram; Saskia T C Neuteboom
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Anti-cancer drugs 2002;13(1):29-36.
2001: Mark D Pegram; C O'Callaghan
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Clinical breast cancer 2001;2 Suppl 1():S15-9.
2001: Gottfried E Konecny; M Fritz; Michael Untch; A Lebeau; Margret Felber; S Lude; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
Breast cancer research and treatment 2001;69(1):53-63.
2001: Gottfried E Konecny; Michael Untch; J Arboleda; C Wilson; Steffen Kahlert; B Boettcher; Margret Felber; Malgorzata Beryt; S Lude; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2448-57.
2001: Gottfried E Konecny; Michael Untch; Dennis J Slamon; Malgorzata Beryt; Steffen Kahlert; Margret Felber; E Langer; S Lude; Hermann Hepp; Mark D Pegram
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Breast cancer research and treatment 2001;67(3):223-33.
2001: Gottfried E Konecny; Michael Untch; A Pihan; Rainer Kimmig; Martina Gropp; Petra Stieber; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1743-9.
2001: Dennis J Slamon; Brian Leyland-Jones; Steven Shak; H Fuchs; Virginia Paton; Alex Bajamonde; T Fleming; Wolfgang Eiermann; JM Wolter; Mark D Pegram; J Baselga; Larry Norton
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
The New England journal of medicine 2001;344(11):783-92.
2001: Dennis J Slamon; Mark D Pegram
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Seminars in oncology 2001;28(1 Suppl 3):13-9.
2001: D B Lackey; M P Groziak; M Sergeeva; Malgorzata Beryt; C Boyer; Robert M Stroud; PH Sayre; J W Park; P Johnston; Dennis J Slamon; H Michael Shepard; Mark D Pegram
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
Biochemical pharmacology 2001;61(2):179-89.
2001: Mark D Pegram
Docetaxel and herceptin: foundation for future strategies.
The oncologist 2001;6 Suppl 3():22-5.
2000: Mark D Pegram; A Lopez; Gottfried E Konecny; Dennis J Slamon
Trastuzumab and chemotherapeutics: drug interactions and synergies.
Seminars in oncology 2000;27(6 Suppl 11):21-5; discussion 92-100.
2000: Mark D Pegram; Dennis J Slamon
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Seminars in oncology 2000;27(5 Suppl 9):13-9.
2000: Gottfried E Konecny; C Crohns; Mark D Pegram; Margret Felber; S Lude; Christian M Kurbacher; Ian Cree; Hermann Hepp; Michael Untch
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Gynecologic oncology 2000;77(2):258-63.
2000: Mark D Pegram; Gottfried E Konecny; Dennis J Slamon
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Cancer treatment and research 2000;103():57-75.
1999: A M Lopez; Mark D Pegram; Dennis J Slamon; Elliot M Landaw
A model-based approach for assessing in vivo combination therapy interactions.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(23):13023-8.
1999: Zuleima Aguilar; Robert W Akita; Richard S Finn; B L Ramos; Mark D Pegram; Fairooz Kabbinavar; Richard J Pietras; Paul I Pisacane; Mark X Sliwkowski; Dennis J Slamon
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Oncogene 1999;18(44):6050-62.
1999: Mark D Pegram
Trastuzumab: a viewpoint by Mark Pegram.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1999;12(2):136-8.
1999: Mark D Pegram; Dennis J Slamon
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
Seminars in oncology 1999;26(4 Suppl 12):89-95.
1999: Mark D Pegram; S Hsu; G Lewis; Richard J Pietras; Malgorzata Beryt; Mark X Sliwkowski; D Coombs; D Baly; Fairooz Kabbinavar; Dennis J Slamon
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Oncogene 1999;18(13):2241-51.
1998: Richard J Pietras; Mark D Pegram; Richard S Finn; D A Maneval; Dennis J Slamon
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Oncogene 1998;17(17):2235-49.
1998: Mark D Pegram; A Lipton; Daniel F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; Dennis J Slamon
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2659-71.
1998: Ralf Landgraf; Mark D Pegram; Dennis J Slamon; David Eisenberg
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Biochemistry 1998;37(9):3220-8.
1998: Mark D Pegram; Giovanni Pauletti; Dennis J Slamon
HER-2/neu as a predictive marker of response to breast cancer therapy.
Breast cancer research and treatment 1998;52(1-3):65-77.
1997: D MacGrogan; Mark D Pegram; Dennis J Slamon; Robert Bookstein
Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas.
Oncogene 1997;15(9):1111-4.
1997: Mark D Pegram; Richard S Finn; K Arzoo; Malgorzata Beryt; Richard J Pietras; Dennis J Slamon
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Oncogene 1997;15(5):537-47.
1995: Richard J Pietras; J Arboleda; D M Reese; N Wongvipat; Mark D Pegram; L Ramos; C M Gorman; M G Parker; Mark X Sliwkowski; Dennis J Slamon
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Oncogene 1995;10(12):2435-46.
1994: Richard J Pietras; B M Fendly; V R Chazin; Mark D Pegram; S B Howell; Dennis J Slamon
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Oncogene 1994;9(7):1829-38.